SSTR5 antagonist 2 is a highly potent, oral active and selective antagonist of somatostatin (receptor) subtype 5 (SSTR5),with potential to treat type 2 diabetes mellitus (T2DM).

Both total and active circulating incretin hormone GLP1 levels in mice at a dose of 10 mg/kg increased by SSTR5 antagonist 2 (10 mg/kg, orally) . SSTR5 antagonist 2 increases pancreatic insulin secretion as well as total and active GLP1 release, and demonstrates synergistic effects in combination with DPP4 inhibitors.